Helomics, MDNA Collaborate
Complete the form below to unlock access to ALL audio articles.
Helomics® Corporation (Helomics), and MDNA Life Sciences, Inc. (MDNA), have announced the beginning of a broad strategic relationship.
As part of this collaboration, Helomics will promote MDNA’s Prostate Core Mitomic Test™ and its liquid biopsy Prostate Mitomic Test™ in selected U.S. markets and will offer these proprietary tests in its CLIA-approved clinical laboratory. Additionally, the companies will work together to develop, validate, and commercialize other liquid biopsy-based diagnostic tests utilizing MDNA’s proprietary Mitomic Technology™ platform, which exploits the unique biological characteristics of mitochondrial DNA. MDNA also intends to grant Helomics a license to offer diagnostic tests, based on MDNA’s proprietary mitochondrial DNA technology, to Helomics’ clients in the pharmaceutical, diagnostic, and biotechnology industries as part of its Contract Research Services offering.
Gerald J. Vardzel Jr., President and CEO of Helomics said, “We are very excited about this strategic collaboration with MDNA. We anticipate that, by leveraging the core expertise of both companies, many new diagnostic tests will be developed and commercialized that will lead to a better understanding of the uniqueness of a patient’s cancer.” Donald L. Very, Jr., Vice President of Research and Commercial Development at Helomics added, “MDNA is the leading developer of mitochondrial DNA-based diagnostic tests. Their Mitomic Technology™ platform has the potential to discover novel biomarkers of disease onset, progression, or regression. This platform will be a significant addition to our research service offerings to our partner-clients in the pharmaceutical and diagnostics industries.”
Chris Mitton, President and CEO of MDNA stated, “Helomics’ truly integrated approach to Contract Research Services, which connects key academic centers and leading pharmaceutical companies with innovative diagnostic platforms, creates a unique opportunity for us to expand access to our proprietary Mitomic Technology™ for rapid biomarker discovery across multiple oncology categories. This strategic relationship with Helomics will enable us to accelerate product development, clinical validation, and the commercialization of our deep pipeline of novel, best-in-class liquid biopsy tests.”
This article has been republished from materials provided by Helomics. Note: material may have been edited for length and content. For further information, please contact the cited source.